Akanda (AKAN) Competitors $3.66 -0.37 (-9.18%) Closing price 04:00 PM EasternExtended Trading$3.66 +0.00 (+0.14%) As of 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock AKAN vs. RLYB, SONN, TAOX, BCAB, CING, NNVC, NAII, PASG, CTXR, and QTTBShould you be buying Akanda stock or one of its competitors? The main competitors of Akanda include Rallybio (RLYB), Sonnet BioTherapeutics (SONN), Synaptogenix (TAOX), BioAtla (BCAB), Cingulate (CING), NanoViricides (NNVC), Natural Alternatives International (NAII), Passage Bio (PASG), Citius Pharmaceuticals (CTXR), and Q32 Bio (QTTB). These companies are all part of the "pharmaceutical products" industry. Akanda vs. Its Competitors Rallybio Sonnet BioTherapeutics Synaptogenix BioAtla Cingulate NanoViricides Natural Alternatives International Passage Bio Citius Pharmaceuticals Q32 Bio Rallybio (NASDAQ:RLYB) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership. Does the media prefer RLYB or AKAN? In the previous week, Akanda had 3 more articles in the media than Rallybio. MarketBeat recorded 6 mentions for Akanda and 3 mentions for Rallybio. Rallybio's average media sentiment score of 0.94 beat Akanda's score of 0.09 indicating that Rallybio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rallybio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akanda 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation & earnings, RLYB or AKAN? Akanda has higher revenue and earnings than Rallybio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRallybio$640K35.04-$57.78M-$0.94-0.57Akanda$840K2.00-$4.10MN/AN/A Which has more risk and volatility, RLYB or AKAN? Rallybio has a beta of -1.12, indicating that its stock price is 212% less volatile than the S&P 500. Comparatively, Akanda has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Do institutionals & insiders hold more shares of RLYB or AKAN? 90.3% of Rallybio shares are owned by institutional investors. Comparatively, 1.0% of Akanda shares are owned by institutional investors. 8.7% of Rallybio shares are owned by company insiders. Comparatively, 20.4% of Akanda shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is RLYB or AKAN more profitable? Akanda has a net margin of 0.00% compared to Rallybio's net margin of -5,473.33%. Akanda's return on equity of 0.00% beat Rallybio's return on equity.Company Net Margins Return on Equity Return on Assets Rallybio-5,473.33% -71.66% -65.06% Akanda N/A N/A N/A Do analysts prefer RLYB or AKAN? Rallybio currently has a consensus price target of $5.00, indicating a potential upside of 831.79%. Given Rallybio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Rallybio is more favorable than Akanda.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Akanda 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryAkanda beats Rallybio on 8 of the 13 factors compared between the two stocks. Get Akanda News Delivered to You Automatically Sign up to receive the latest news and ratings for AKAN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKAN vs. The Competition Export to ExcelMetricAkandaMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.68M$10.68B$5.76B$9.75BDividend YieldN/A1.87%3.95%4.02%P/E RatioN/A21.7931.4426.39Price / Sales2.0030.09431.83159.31Price / CashN/A24.7837.7559.42Price / Book0.393.4910.566.59Net Income-$4.10M$211.94M$3.27B$265.83M7 Day Performance-7.05%1.47%0.60%0.19%1 Month Performance-15.74%13.45%5.43%2.15%1 Year Performance-49.95%-7.11%50.38%21.08% Akanda Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKANAkanda0.8455 of 5 stars$3.66-9.2%N/A-44.4%$1.68M$840K0.00110Gap DownRLYBRallybio2.993 of 5 stars$0.60+2.5%$5.00+738.1%-51.7%$24.93M$640K-0.6340News CoverageGap DownSONNSonnet BioTherapeutics3.4814 of 5 stars$3.61+0.6%$20.00+454.0%-41.9%$24.38M$1M0.0010Positive NewsGap DownTAOXSynaptogenixN/A$6.96-0.7%N/AN/A$24.29MN/A-0.354Positive NewsBCABBioAtla2.4223 of 5 stars$0.41+14.2%$5.00+1,129.7%-76.5%$23.88M$11M-0.3760Gap UpHigh Trading VolumeCINGCingulate2.3808 of 5 stars$4.30+2.1%$26.25+510.5%-50.8%$23.26MN/A-1.0520Analyst RevisionNNVCNanoViricides0.433 of 5 stars$1.43-3.4%N/A-25.9%$22.98MN/A-1.9920NAIINatural Alternatives International1.4563 of 5 stars$3.67-7.1%N/A-31.1%$22.68M$113.80M-2.64290Gap DownHigh Trading VolumePASGPassage Bio3.9112 of 5 stars$7.13-4.7%$91.75+1,186.8%-50.8%$22.67MN/A-0.39130CTXRCitius Pharmaceuticals2.8377 of 5 stars$1.32+4.8%$53.00+3,915.2%-90.3%$22.46MN/A0.0020Gap UpQTTBQ32 Bio2.4647 of 5 stars$1.82-7.6%$12.17+568.5%-95.4%$22.20MN/A-0.4239News Coverage Related Companies and Tools Related Companies RLYB Competitors SONN Competitors TAOX Competitors BCAB Competitors CING Competitors NNVC Competitors NAII Competitors PASG Competitors CTXR Competitors QTTB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKAN) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akanda Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akanda With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access